Frequency of Growth Hormone in the Etiology of Short Stature and Treatment of the Deficient Cases With Exogenous Recombinant Growth Hormone

İsmail GÖÇMEN; Ferhan KARADEMİR; Orhan ERKAN; Ayhan KILIÇ; Selami  SÜLEYMANOĞLU; Yaşar TÜLBEK

doi:10.58600/eurjther.1995-6-2-1523-arch

Authors

İsmail GÖÇMEN GATA Haydarpaşa Eğt.Hast.Çocuk Sağlığı ve Hastalıkları Kliniği,Yrd.Doç.Dr.
Ferhan KARADEMİR GATA Haydarpaşa Eğt.Hast.Çocuk Sağlığı ve Hası.Kliniği, Uzm.Dr.
Orhan ERKAN GATA Haydarpaşa Eğt.Hast.Çocuk Sağlığı ve Hastalıkları Kliniği,Uzm.Öğr.
Ayhan KILIÇ GATA Haydarpaşa Eğt.Hast.Çocuk Sağlığı ve Hastalıkları Kliniği,Uzm.Öğr.
Selami SÜLEYMANOĞLU GATA Haydarpaşa Eğt.Hast.Çocuk Sağlığı ve Hastalıkları Kliniği,Uzm.Öğr.
Yaşar TÜLBEK GATA Haydarpaşa Eğt.Hast.Nefrolo;i Kliniği,Doç.Dr.

DOI:

https://doi.org/10.58600/eurjther.1995-6-2-1523-arch

Keywords:

Growth Hormone, Short Stature

Abstract

Sixty patients who had been referred to our out patient clinic with the complaint of short stature and whose heights were found to be below 2 Standart Deviation Scores (SDS) of agerelated values were investigated to evaluate the effect of recombinant hGH treatment. Twenty-three (38.3 %) had hasal levels of Growth Hormone (GH) and bone age retardation along with heights 2 SDS below normal .. Insulin-induced hypoglycemia and L-OOPA stimulation tests were applied to these cases. Seven cases (30.49 %) gave a complete response to these tests, while 3 cases (13.04 %) gave partial response and 13 cases (56.52 %) gave no response at all.

Seven of the 13 patients with isolated GH deficiency were given recombinant GH 12 IU/m2 /week, subcutaneously, 6 days a week. These patients have not completed the treatment course. Reevaluation at the end of one year's therapy revealed a statistically significant difference in their growth velocities (p<0.05). We conclude that exogenous recombinant hGH is effective in the treatment of short stature due to isolated GH deficiency, and even betler responses can be achieved as the patients are recognized and treated earlier.

Metrics

Metrics Loading ...

References

Tanner JM, Whitehouse RH:Clinical Longitudinal Standards for Height, Weight, Height Velocity, Weight Velocitiy and Stages of Puberty. Arch Dis Child 51: 170-179, 1976.

Tanner JM, Whitehouse RH, Takaishi M:Standards From Birth to Maturity for Height, Weight, Height Velocity and Weight Velocity:British Children 1965. Parts 1 and 2.Arch Dis Child 41:454-471 and 613-635, 1966.

Root AW, Diamond F:The Pituitary Glan, in Kelly VC(ed):Practice of Pediatrics, Philadelphia, Harper & Row, 1982, p 181.

Hung W: Clinical Pediatric Endocrinology. 1992 by Mosby-Year Book, inc.St.Louis. p 73-76.

Raben MS:Treatment ofa Pituitary DwarfHuman Growth Honnone. J Clin Endocrinol Metab 18:901-903, 1958.

Powell-Jackson J, Weller RO, Kennedy P et al:Creutzfeld-Jakop Disease After Administration ofHuman Growth Honnone. Lancet 2:244-246, 1985.

Gibbs CJ Jr, Joy A, Heffner R et al:Clinical and Pathological Features and Laboratory Confinnation ofCreutzfeld-Jakop Disease in a Recipient ofHuman Pituitaıy-Derived Huma:n Growth Honnone. N Engl J Med 734-738, 1985.

Koch TK, Berg BO, Annond SJ, Gravina RF:Creutzfeld-Jakob Disease in a Young Adult with Idiopathic Hypopituitarism:Possible Relation to the Administration of Cadaveric Human Growth Honnone. N Engl J Med 313: 731-734, 1 985.

Sandahl-Christiarısen J, Orskov H, Binder C, Kastrup KW:İmitation of Normal Plasma Growth Hormone Profile by Subcutaneous Administration of Human Growth Honnone to GrowthHonnone Deficient Children. Acta Endocrinol 102:6-10, 1983.

Albertsson-Wikland K, Westphal O, Wetrgren V:Daily Subcutaneous Administration of Human Growth Hormone in Growth Honnone Deficient Children. Acta Paediatr Scand 75?89- 97, 1986.

Tanner JM, Hughes PCR, Whitehouse RH:Comparative Rapidity ofResponse ofHeight, Limb Muscle and Limb Fat to Treatment with Hııman Growth Honnone in Patients with and without Growth Honnone Deficiency. Acta Endocrinol;84:68 l-696, 1977.

Milner RDG, Flodh H(eds):Immunological Aspects of Human Growth Honnone. Oxford:Medical Education Services, 1985.

Neyzi o, Ertuğrul T:Büyüme ve Gelişme, irt Pediatri. 1989 by Nobel Tıp Kitapevi, p 66-70. 14. Root AW, Diamond F:The pituitary gland, in Kelly VC(ed):Practice of Pediatrics, Philadelphia, Harper & Row, 1982, p 181.

Frasier SD:Human Pituitary Growth Hormone (hGH) Therapy in Growth Honnone Deficiency. Endocr Rev 4: 155-70, 1983.

Kaplan SL, Underwood LE, August GP et al:Clinical Studies with Recombinant-DNADerived Methionly Human Growth Honnone in Growth Hormone Deficient Children. Lancet 1 :697-700, 1986.

Albertsson-Wikland K, Aronson S, Nilsson P:Authentic Recombinant Human Growth Honnone Results of a Multicenter Clinical Trial in Patients With Growth Honnone Deficiency. Helv Paediatr Acta 43:443-8, 1988.

Takano K, Shizume K, Hibi I et al:Clinical Trial with Authentic Recombinant Somatotropin in Japan. Acta Paediatr Scand Suppl 331: 18-24, 1987.

KeUer E, et al:Growth Disorders in:Cavallo L, Job JC, New MJ(ed):The State of the Art. Serono Symposia, Raven Press Vol 81: 309, 1991.

Ranke MB, Bierich JR:Clinical Experience With Authentic Recombinant Somatropin. German Collaborative Study. Acta Paediatr Scand Suppl 331 :9-17, 1987.

Holcornbe JH, Confortı PM, Wonk AC, et al:Biosynthetic Hııman Growth Honnone in the Treatment of Growth Hormone Deficiency. Acta Paediatr Scand Suppl 367:44-48, 1990.

Öcal G, Berberoğlu M, Akçurin S:Büyüme Hormonu Eksikli Çocuklarda Uzun Süreli Büyüme Hormonu Tedavisinin Sonuçları. (Abstract) XXXVI.Milli Pediatri kongresi özet Kitapçığı, 1992.